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Age-specific familial risks for renal cell carcinoma with evidence
on recessive heritable effects.
Background. Systematic comparisons of mode of inheritance
for renal cell carcinoma (RCC) have not been carried out. The
occurrence of cancer in parents and offspring may be due to
dominant causes, whereas cancer affecting only siblings may
indicate a recessive causation. Environmental effects need to
be excluded.
Methods. The Swedish Family-Cancer Database includes all
Swedes born after 1931 with their biologic parents, totaling
10.2 million persons. Cancer data were retrieved from the
Swedish Cancer Registry from years 1961 to 2000, included 2415
cases of RCC in offspring and 18531 in parents. Standardized
incidence ratios (SIRs) and 95% CI limits were calculated for
offspring whose parents or sibling were diagnosed with RCC.
Results. The SIRs for siblings for RCC depended on their
age difference. SIR was 7.63 (95% CI 3.63–14.08) when the age
difference was less than 3 years and compared to 3.43 (95%
CI 1.77–6.02) for large age difference. SIRs for familial risk of
RCC were 1.73 (95% CI 1.31–2.26) when a parent and 4.58 (95%
CI 2.87–6.94) when a sibling had RCC. Age-specific analysis of
familial RCC among siblings revealed maxima at ages 40 to 49
and 60 to 68 years.
Conclusion. The findings in the present study offer evidence
on recessive effects in early onset RCC.
Renal cell carcinoma (adenocarcinoma of the renal
parenchyma) (RCC) is the most common cancer in the
kidney, accounting for approximately 85% of all renal
neoplasms. Most RCCs are of clear cell type and they har-
bor somatic mutations in the von Hippel Lindau (VHL)
gene [1–4]. Risk factors of RCC include tobacco smok-
ing, obesity, components of diet, some occupational ex-
posures, and family history [5–9]. Over 2% of the Swedish
RCC patients have a parent with RCC, and the familial
risk has been about 1.6 in Sweden and the United States
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[10–12]. RCC is a manifestation in VHL syndrome, affect-
ing half of mutation carriers in the VHL gene; central ner-
vous system hemangioblastomas, and ocular angiomas
are other manifestations in VHL disease [13–16]. RCC
is also related to rare familial clusters with or without
chromosome 3 translocations and other syndromes, such
as tuberous sclerosis and Birt-Hogg-Dube syndrome [17–
19]. The inheritance of RCC is dominant in these cancer
syndromes and parent-to-offspring transmission is also
detected in population-based studies on familial aggre-
gation of RCC [10–12]. However, risk for RCC among
siblings has been higher than that between offspring and
parents, which could indicate some contribution by a re-
cessive mode of inheritance [20–23].
The aim of the present study is to carry out an age-
specific analysis of familial RCC using the newest update
of the nation-wide Swedish Family-Cancer Database [24].
We want particularly to investigate the role of possible
recessive effects in RCC, which are inferred when the
risks among siblings without affected parents exceed the
risks for offspring of affected parents. The results would
propose an entirely new strategy for gene identification
efforts. However, the inference is guarded by childhood
shared environmental effects, because they increase fa-
milial risk among siblings, which makes them indistin-
guishable from recessive effects [25, 26]. We believe that
the comparison of familial risks between siblings accord-
ing to their age difference is a solution to this problem;
to our knowledge such analysis is novel for RCC. The
Database covers over 10 million people registered in fam-
ilies and 1 million medically verified cancers, providing
excellent opportunities for genetic epidemiology.
METHODS
Statistics Sweden maintains a “Multigeneration Reg-
ister” where children, offspring, born in Sweden in
1932 and later, are registered with their parents (those
pleading parenthood at birth) and they are organized as
families [24]. Information on the database is also avail-
able at the Nature Genetics website as ‘Supplementary
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Fig. 1. Age-specific incidence of renal cell
carcinoma (RCC) in offspring of parental and
sibling probands.
information’ [27]. The data on families and cancers have
a complete coverage, baring some groups of deceased
offspring, which affect those born in the 1930s and who
died before 1991. Although this small group of offspring
with missing links to parents has negligible effect on the
estimates of familial risk [28], we limited the present
study to offspring whose parents were known, to elim-
inate possibility of bias. This “Multigeneration Register”
was linked by the individually unique national registra-
tion number to the Cancer Registry from years 1958
to 2000. Cancer registration is considered to be close
to 100% currently [29]. Only the first primary RCCs
were considered. A four-digit diagnostic code accord-
ing to the 7th revision of the International Classifica-
tion of Diseases (ICD-7) was used; the code 1800 was
used for RCC. The histologic classification of RCCs was
used, as present in the Cancer Registry, to define ade-
nocarinoma (pathology codes 096) and Wilms’ tumor
(886); only adenocarcinoma was included. These codes
have been used since the start of cancer registration in
Sweden (WHO/HS/CANC/24.1 Histology Code). From
year 1993 onward, ICD-O-2/ICD with histopathologic
data according to the Systematized Nomenclature of
Medicine (SNOMED) (http://snomed.org) was used.
Standardized incidence ratios (SIRs) were used to
measure cancer risks for offspring according to occur-
rence of cancers in their families. When more than two
affected offspring were found in any family, they were
counted as independent events. No family with multi-
ple affected siblings had an affected parent. SIRs were
calculated for offspring whose parent or sibling had the
same, concordant cancer (i.e., using parents or siblings
as probands). Follow-up was started for each offspring at
birth, immigration, or January 1, 1961, whichever came
latest. Follow-up was terminated on diagnosis of first can-
cer, death, emigration, or the closing date of the study,
December 31, 2000.
Parents’ ages were not limited but offspring were 0 to
68 years of age. All tumor incidence rates were based
on the data in the Family-Cancer Database, and they
were essentially similar to rates in the Swedish Cancer
Registry. Rates were standardized to the European pop-
ulation. SIRs were calculated as the ratio of observed
(O) to expected (E) number of cases. The expected num-
bers were calculated from 5-year age, gender, tumor type,
period (5-year bands), socioeconomic status (six groups,
including farmers, manual workers, blue collar workers,
professionals, self employed, and others), and residential
area (three groups, including the three largest cities of
Stockholm, Gothenburg, and Malmo, southern counties
and northern counties), specific standard incidence rates
for all offspring lacking a family history [30]. Confidence
intervals (95% CI) were calculated assuming a Poisson
distribution [30]. Risks for siblings were calculated us-
ing the cohort method, described elsewhere [20]. This
method is not sensitive to the sibship size [20]; however,
based on a previous analysis from the Database, neither
sibship size nor birth order are related to risk of RCC
[31]. The analysis of this study was implemented in the
environment of the SAS, release 8.2.
RESULTS
The Family-Cancer Database covered years 1961 to
2000 from the Swedish Cancer Registry and it included
1516 sons and 899 daughters RCCs between ages 0 to
68 years, in addition to 11137 fathers and 7394 mothers
RCCs. Age-specific incidence rates of RCC in offspring
according to family history are shown in Figure 1. Early
onset incidence maximum for RCC among siblings oc-
curred at ages 30 to 34 and 45 to 49 years; offspring of af-
fected parents showed a peak incidence at 50 to 59 years.
Table 1 presents the risk for RCC among siblings ac-
cording to their age difference. Age difference associated
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Table 1. Standardized incidence ratio (SIR) for renal cell carcinoma (RCC) in siblings by age difference
Sibling ages < 3 years Sibling ages ≥ 3 yearsAge at diagnosis
years Observed SIR 95% CI Observed SIR 95% CI
<50 2 5.95 0.56 21.87 5 4.44 1.40 10.43
≥50 8 8.21 3.51 16.25 7 2.96 1.17 6.13
All 10 7.63 3.63 14.08 12 3.43 1.77 6.02
Bold type signifies 95% CIs do not include 1.00.
Table 2. Standardized incidence ratio (SIR) for renal cell carcinoma (RCC) in offspring of parents and sibling probands
Parental proband Sibling probandAge at diagnosis SIR ratio
years Observed SIR 95% CI Observed SIR 95% CI (sibling/parent)
<50 22 1.87 1.17 2.84 7 4.78 1.90 9.91 2.6
≥50 33 1.65 1.14 2.33 15 4.49 2.50 7.42 2.7
All 55 1.73 1.31 2.26 22 4.58 2.87 6.94 2.6
Bold type signifies 95% CIs do not include 1.00.
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Fig. 2. Familial standardized incidence ra-
tio (SIR) for offspring renal cell carci-
noma (RCC) when parents or siblings were
probands. The numbers indicate the number
of cases and the stars show that the 95% CIs
do not include 1.00.
with the risk of cancer. Those born less than 3 years apart
had higher risks. Among those born with a large age dif-
ference, the risk was twofold higher in the young age
group (diagnoses before age 50 years) than in the older
one. Among the total of 22 affected siblings, two were di-
agnosed with a second primary brain hemangioblastoma
(ages at diagnosis of first primary RCC were 45 and 50
years; diagnostic ages for the second primary brain he-
mangioblastomas were 50 and 54 years, respectively).
Age-specific familial risks for RCC were analyzed us-
ing parents or siblings as probands (Table 2). The overall
SIRs were 1.73 (95% CI 1.31–2.26) and 4.58 (95% CI
2.87–6.94), respectively. These were approximately 2.5-
fold higher among siblings than between offspring and
parents. The SNOMED histology was available only from
year 1993 onward, and thus few cases were retrieved. For
clear cell adenocarcinoma, the SIR was 2.99 (N = 12, 95%
CI 1.54–5.34) when a parent had RCC. Only two affected
sibling pairs were identified. Among the 12 clear cell ade-
nocarcinoma families, other cancers included prostate,
liver, thyroid, and cervical cancer, one case in each fam-
ily member.
Figure 2 shows the age-specific SIRs for RCC when par-
ents or siblings were used as probands. The SIRs showed
a prominent early age onset maximum between ages 40 to
49 years when siblings (SIR = 5.13, 95% CI 1.85–11.25) or
parents were probands (SIR = 2.03, 95% CI 1.20–3.21).
The proportion of familial cases belonging to the early
onset component up to the age 50 years was 32% and
40% by sibling or parental proband, respectively.
In the Database, eight families had an offspring af-
fected by first primary brain hemangioblastoma and sec-
ond primary RCC. Because the present study only cov-
ered first primary cancers, these RCCs were not included
in the analysis.
DISCUSSION
Familial aggregation of cancer may be due to environ-
mental factors shared by family members or due to shared
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genes [25, 32]. The risk of kidney cancer shows no correla-
tion between spouses, suggesting that there are no strong
environmental factors that could explain the familial ag-
gregation. However, spouse concordance will not detect
environmental sharing early in life. Migrant studies from
Sweden show that the patterns for most cancers, includ-
ing kidney cancer, in immigrants are largely set during
the two first decades of life [33, 34]. For these reasons, we
considered important to examine the possible effects of
shared childhood environment, which we accomplished
by comparing risks for RCC between siblings according
to their age difference. The results suggested that there
was an effect of age difference in cancers diagnosed after
age 50 years but not in those diagnosed before. We con-
clude that childhood sharing is probably not important
for RCC diagnosed before age 50 years.
A larger familial risk among siblings whose parents
were unaffected compared to offspring of affected par-
ents, as shown in the present study, would provide ev-
idence on a recessive effect. However, such data fail to
discriminate between recessive and X-linked inheritance.
If a disease was X-linked, it would affect mainly men. For
RCC a large X-linked effect is unlikely because a recent
study from this Database showed that there was no gen-
der effect in familial kidney cancer [35]. We thus conclude
that our data provide evidence of recessive inheritance,
at least in early-onset RCC.
A dominant predisposition to RCC in association with
VHL disease is well documented and 24% to 45% of pa-
tients with a mutated VHL gene develop clear cell RCC
during their lives [36]. In the present analysis, we found
only two RCC cases among the siblings (2/22 = 9%) with
features of a VHL disease [36]. The high familial cluster-
ing of RCC among siblings is therefore unlikely to be ex-
plained by the occurrence of the VHL disease. Because
even the other known familial clusters of RCC, includ-
ing chromosome 3 translocations, tuberous sclerosis, and
Birt-Hogg-Dube syndrome, show dominant inheritance,
we suggest that our findings point to a yet unknown re-
cessive condition [17–19].
There has been no population-based studies on reces-
sive effects in RCC, which probably explains the current
lack of knowledge in this area. The detection of recessive
conditions is difficult because the cases appear apparently
randomly in pedigrees but often reveal consanguinity at
a closer inspection. Population geneticists have raised
questions about the relatively small number of known
human recessive syndromes. In species of experimental
animals recessive traits predominate as opposed to hu-
mans where dominant traits are more common [37].
CONCLUSION
The present study offers further evidence of recessive
susceptibility genes in early-onset RCC [23]. Unfortu-
nately, individuals in the Family-Cancer Database are
anonymous and we have no direct possibility to search
for possible consanguinity in the affected families. If con-
sanguinity was confirmed, the strategy for finding the
putative recessive gene(s) would be mapping for homozy-
gosity for alleles in the affected individuals.
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